

Bradley J Turner

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/756373/publications.pdf>

Version: 2024-02-01

80
papers

4,819
citations

94433

37
h-index

102487

66
g-index

82
all docs

82
docs citations

82
times ranked

6689
citing authors

#	ARTICLE	IF	CITATIONS
1	TDP-43 Triggers Mitochondrial DNA Release via mPTP to Activate cGAS/STING in ALS. <i>Cell</i> , 2020, 183, 636-649.e18.	28.9	453
2	Transgenics, toxicity and therapeutics in rodent models of mutant SOD1-mediated familial ALS. <i>Progress in Neurobiology</i> , 2008, 85, 94-134.	5.7	435
3	Intercellular propagated misfolding of wild-type Cu/Zn superoxide dismutase occurs via exosome-dependent and -independent mechanisms. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014, 111, 3620-3625.	7.1	373
4	Induction of the Unfolded Protein Response in Familial Amyotrophic Lateral Sclerosis and Association of Protein-disulfide Isomerase with Superoxide Dismutase 1. <i>Journal of Biological Chemistry</i> , 2006, 281, 30152-30165.	3.4	252
5	Impaired Extracellular Secretion of Mutant Superoxide Dismutase 1 Associates with Neurotoxicity in Familial Amyotrophic Lateral Sclerosis. <i>Journal of Neuroscience</i> , 2005, 25, 108-117.	3.6	175
6	The bone morphogenetic protein axis is a positive regulator of skeletal muscle mass. <i>Journal of Cell Biology</i> , 2013, 203, 345-357.	5.2	166
7	Oral Treatment with Cull(atm) Increases Mutant SOD1 In Vivo but Protects Motor Neurons and Improves the Phenotype of a Transgenic Mouse Model of Amyotrophic Lateral Sclerosis. <i>Journal of Neuroscience</i> , 2014, 34, 8021-8031.	3.6	161
8	Emerging therapies and challenges in spinal muscular atrophy. <i>Annals of Neurology</i> , 2017, 81, 355-368.	5.3	157
9	ALS-Associated TDP-43 Induces Endoplasmic Reticulum Stress, Which Drives Cytoplasmic TDP-43 Accumulation and Stress Granule Formation. <i>PLoS ONE</i> , 2013, 8, e81170.	2.5	141
10	The Hippo pathway effector YAP is a critical regulator of skeletal muscle fibre size. <i>Nature Communications</i> , 2015, 6, 6048.	12.8	128
11	Diacetylbis(N(4)-methylthiosemicarbazonato) Copper(II) (Cull(atm)) Protects against Peroxynitrite-induced Nitrosative Damage and Prolongs Survival in Amyotrophic Lateral Sclerosis Mouse Model. <i>Journal of Biological Chemistry</i> , 2011, 286, 44035-44044.	3.4	123
12	Association of Regulatory T-Cell Expansion With Progression of Amyotrophic Lateral Sclerosis. <i>JAMA Neurology</i> , 2018, 75, 681.	9.0	120
13	SYT1-associated neurodevelopmental disorder: a case series. <i>Brain</i> , 2018, 141, 2576-2591.	7.6	98
14	Antisense peptide nucleic acid-mediated knockdown of the p75 neurotrophin receptor delays motor neuron disease in mutant SOD1 transgenic mice. <i>Journal of Neurochemistry</i> , 2003, 87, 752-763.	3.9	91
15	Disease Mechanisms in ALS: Misfolded SOD1 Transferred Through Exosome-Dependent and Exosome-Independent Pathways. <i>Cellular and Molecular Neurobiology</i> , 2016, 36, 377-381.	3.3	80
16	Dysregulation of the complement cascade in the hSOD1G93A transgenic mouse model of amyotrophic lateral sclerosis. <i>Journal of Neuroinflammation</i> , 2013, 10, 119.	7.2	76
17	SOD1 protein aggregates stimulate macropinocytosis in neurons to facilitate their propagation. <i>Molecular Neurodegeneration</i> , 2015, 10, 57.	10.8	68
18	Rilmenidine promotes MTOR-independent autophagy in the mutant SOD1 mouse model of amyotrophic lateral sclerosis without slowing disease progression. <i>Autophagy</i> , 2018, 14, 534-551.	9.1	66

#	ARTICLE	IF	CITATIONS
19	Ferroptosis mediates selective motor neuron death in amyotrophic lateral sclerosis. <i>Cell Death and Differentiation</i> , 2022, 29, 1187-1198.	11.2	63
20	Survival motor neuron deficiency enhances progression in an amyotrophic lateral sclerosis mouse model. <i>Neurobiology of Disease</i> , 2009, 34, 511-517.	4.4	62
21	TDP-43 mutations causing amyotrophic lateral sclerosis are associated with altered expression of RNA-binding protein hnRNP K and affect the Nrf2 antioxidant pathway. <i>Human Molecular Genetics</i> , 2017, 26, 1732-1746.	2.9	62
22	Mutant SOD1 inhibits ER-Golgi transport in amyotrophic lateral sclerosis. <i>Journal of Neurochemistry</i> , 2014, 129, 190-204.	3.9	61
23	Antisense peptide nucleic acid targeting GluR3 delays disease onset and progression in the SOD1 G93A mouse model of familial ALS. <i>Journal of Neuroscience Research</i> , 2004, 77, 573-582.	2.9	59
24	Perturbed BMP signaling and denervation promote muscle wasting in cancer cachexia. <i>Science Translational Medicine</i> , 2021, 13, .	12.4	58
25	Synapse Dysfunction of Layer V Pyramidal Neurons Precedes Neurodegeneration in a Mouse Model of TDP-43 Proteinopathies. <i>Cerebral Cortex</i> , 2017, 27, 3630-3647.	2.9	56
26	Necroptosis is dispensable for motor neuron degeneration in a mouse model of ALS. <i>Cell Death and Differentiation</i> , 2020, 27, 1728-1739.	11.2	56
27	ER Stress and UPR in Familial Amyotrophic Lateral Sclerosis. <i>Current Molecular Medicine</i> , 2006, 6, 79-86.	1.3	55
28	TDP-43 expression in mouse models of amyotrophic lateral sclerosis and spinal muscular atrophy. <i>BMC Neuroscience</i> , 2008, 9, 104.	1.9	55
29	Dismutase-competent SOD1 mutant accumulation in myelinating Schwann cells is not detrimental to normal or transgenic ALS model mice. <i>Human Molecular Genetics</i> , 2010, 19, 815-824.	2.9	52
30	Effect of p75 neurotrophin receptor antagonist on disease progression in transgenic amyotrophic lateral sclerosis mice. <i>Journal of Neuroscience Research</i> , 2004, 78, 193-199.	2.9	51
31	HspB8 mutation causing hereditary distal motor neuropathy impairs lysosomal delivery of autophagosomes. <i>Journal of Neurochemistry</i> , 2011, 119, 1155-1161.	3.9	49
32	Phosphorylation of hnRNP K by cyclin-dependent kinase 2 controls cytosolic accumulation of TDP-43. <i>Human Molecular Genetics</i> , 2015, 24, 1655-1669.	2.9	48
33	Mutant TDP-43 Deregulates AMPK Activation by PP2A in ALS Models. <i>PLoS ONE</i> , 2014, 9, e90449.	2.5	46
34	Neuromuscular accumulation of mutant superoxide dismutase 1 aggregates in a transgenic mouse model of familial amyotrophic lateral sclerosis. <i>Neuroscience Letters</i> , 2003, 350, 132-136.	2.1	43
35	Amyotrophic Lateral Sclerosis and Autophagy: Dysfunction and Therapeutic Targeting. <i>Cells</i> , 2020, 9, 2413.	4.1	41
36	Misfolded Polyglutamine, Polyalanine, and Superoxide Dismutase 1 Aggregate via Distinct Pathways in the Cell. <i>Journal of Biological Chemistry</i> , 2014, 289, 6669-6680.	3.4	39

#	ARTICLE	IF	CITATIONS
37	Overexpression of survival motor neuron improves neuromuscular function and motor neuron survival in mutant SOD1 mice. <i>Neurobiology of Aging</i> , 2014, 35, 906-915.	3.1	39
38	AMPK Signalling and Defective Energy Metabolism in Amyotrophic Lateral Sclerosis. <i>Neurochemical Research</i> , 2016, 41, 544-553.	3.3	39
39	Toxicity of substrate-bound amyloid peptides on vascular smooth muscle cells is enhanced by homocysteine. <i>FEBS Journal</i> , 2002, 269, 3014-3022.	0.2	38
40	Behavioural and anatomical effects of systemically administered leukemia inhibitory factor in the SOD1G93A G1H mouse model of familial amyotrophic lateral sclerosis. <i>Brain Research</i> , 2003, 982, 92-97.	2.2	38
41	Opposing effects of low and high-dose clozapine on survival of transgenic amyotrophic lateral sclerosis mice. <i>Journal of Neuroscience Research</i> , 2003, 74, 605-613.	2.9	33
42	The beta-amyloid peptide of Alzheimer's disease decreases adhesion of vascular smooth muscle cells to the basement membrane. <i>Journal of Neurochemistry</i> , 2006, 96, 53-64.	3.9	30
43	Characterization of the Stability and Bio-functionality of Tethered Proteins on Bioengineered Scaffolds. <i>Journal of Biological Chemistry</i> , 2014, 289, 15044-15051.	3.4	29
44	Sphingolipids metabolism alteration in the central nervous system: Amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. <i>Seminars in Cell and Developmental Biology</i> , 2021, 112, 82-91.	5.0	28
45	Serum matrix metalloproteinase-9 activity is dysregulated with disease progression in the mutant SOD1 transgenic mice. <i>Neuromuscular Disorders</i> , 2010, 20, 260-266.	0.6	27
46	Transactive Response DNA-Binding Protein 43 Abnormalities after Traumatic Brain Injury. <i>Journal of Neurotrauma</i> , 2019, 36, 87-99.	3.4	26
47	Cortical hyperexcitability: Diagnostic and pathogenic biomarker of ALS. <i>Neuroscience Letters</i> , 2021, 759, 136039.	2.1	24
48	Inhibition of motor neuron death <i>in vitro</i> and <i>in vivo</i> by a p75 neurotrophin receptor intracellular domain fragment. <i>Journal of Cell Science</i> , 2016, 129, 517-30.	2.0	23
49	The P2X7 receptor antagonist JNJ-47965567 administered thrice weekly from disease onset does not alter progression of amyotrophic lateral sclerosis in SOD1G93A mice. <i>Purinergic Signalling</i> , 2020, 16, 109-122.	2.2	23
50	Enhancing survival motor neuron expression extends lifespan and attenuates neurodegeneration in mutant TDP-43 mice. <i>Human Molecular Genetics</i> , 2016, 25, 4080-4093.	2.9	22
51	Thiol-Cyanobenzothiazole Ligation for the Efficient Preparation of Peptide-PNA Conjugates. <i>Bioconjugate Chemistry</i> , 2019, 30, 793-799.	3.6	20
52	Androgen receptor antagonism accelerates disease onset in the SOD1 ^{G93A} mouse model of amyotrophic lateral sclerosis. <i>British Journal of Pharmacology</i> , 2019, 176, 2111-2130.	5.4	19
53	Application of Urine-Derived Stem Cells to Cellular Modeling in Neuromuscular and Neurodegenerative Diseases. <i>Frontiers in Molecular Neuroscience</i> , 2019, 12, 297.	2.9	19
54	Combination of valproic acid and morpholino splice-switching oligonucleotide produces improved outcomes in spinal muscular atrophy patient-derived fibroblasts. <i>Neurochemistry International</i> , 2017, 108, 213-221.	3.8	17

#	ARTICLE	IF	CITATIONS
55	Co-regulation of survival of motor neuron and Bcl-xL expression: Implications for neuroprotection in spinal muscular atrophy. <i>Neuroscience</i> , 2012, 220, 228-236.	2.3	15
56	Effect of thymic stimulation of CD4+ T cell expansion on disease onset and progression in mutant SOD1 mice. <i>Journal of Neuroinflammation</i> , 2015, 12, 40.	7.2	15
57	Glutathione monoethyl ester prevents TDP-43 pathology in motor neuronal NSC-34 cells. <i>Neurochemistry International</i> , 2018, 112, 278-287.	3.8	15
58	Brain β -Amyloid Accumulation in Transgenic Mice Expressing Mutant Superoxide Dismutase 1. <i>Neurochemical Research</i> , 2004, 29, 2281-2286.	3.3	13
59	Stimulation of mTOR-independent autophagy and mitophagy by rilmenidine exacerbates the phenotype of transgenic TDP-43 mice. <i>Neurobiology of Disease</i> , 2021, 154, 105359.	4.4	13
60	Functional characterisation of the amyotrophic lateral sclerosis risk locus GPX3/TNIP1. <i>Genome Medicine</i> , 2022, 14, 7.	8.2	12
61	Dysregulation of Steroid Hormone Receptors in Motor Neurons and Glia Associates with Disease Progression in ALS Mice. <i>Endocrinology</i> , 2020, 161, .	2.8	11
62	Inducible superoxide dismutase 1 aggregation in transgenic amyotrophic lateral sclerosis mouse fibroblasts. <i>Journal of Cellular Biochemistry</i> , 2004, 91, 1074-1084.	2.6	10
63	Endosomal escape cell-penetrating peptides significantly enhance pharmacological effectiveness and CNS activity of systemically administered antisense oligonucleotides. <i>International Journal of Pharmaceutics</i> , 2021, 599, 120398.	5.2	10
64	The Amyotrophic Lateral Sclerosis M114T PFN1 Mutation Deregulates Alternative Autophagy Pathways and Mitochondrial Homeostasis. <i>International Journal of Molecular Sciences</i> , 2022, 23, 5694.	4.1	10
65	Could an Impairment in Local Translation of mRNAs in Glia be Contributing to Pathogenesis in ALS?. <i>Frontiers in Molecular Neuroscience</i> , 2019, 12, 124.	2.9	9
66	Modular Synthesis of Trifunctional Peptide-oligonucleotide Conjugates via Native Chemical Ligation. <i>Frontiers in Chemistry</i> , 2021, 9, 627329.	3.6	9
67	Mutant TDP-43 Expression Triggers TDP-43 Pathology and Cell Autonomous Effects on Primary Astrocytes: Implications for Non-cell Autonomous Pathology in ALS. <i>Neurochemical Research</i> , 2020, 45, 1451-1459.	3.3	7
68	Design and application of a peptide nucleic acid sequence targeting the p75 neurotrophin receptor. <i>Biorganic and Medicinal Chemistry Letters</i> , 2003, 13, 2377-2380.	2.2	5
69	Chemotherapy Delays Progression of Motor Neuron Disease in the SOD1 G93A Transgenic Mouse. <i>Chemotherapy</i> , 2004, 50, 138-142.	1.6	5
70	Alzheimer's Disease Therapeutics: New Approaches to an Ageing Problem. <i>IUBMB Life</i> , 2004, 56, 203-208.	3.4	5
71	<i>GAL</i> receptor knockout mice exhibit an alcohol preferring phenotype. <i>Addiction Biology</i> , 2019, 24, 886-897.	2.6	5
72	Lipid Metabolism Is Dysregulated in the Motor Cortex White Matter in Amyotrophic Lateral Sclerosis. <i>Metabolites</i> , 2022, 12, 554.	2.9	5

#	ARTICLE	IF	CITATIONS
73	Exploring germline recombination in Nestin ^{Cre} transgenic mice using floxed androgen receptor. <i>Genesis</i> , 2020, 58, e23390.	1.6	4
74	The Assembly of Fluorescently Labeled Peptide-Oligonucleotide Conjugates via Orthogonal Ligation Strategies. <i>Methods in Molecular Biology</i> , 2018, 1828, 355-363.	0.9	3
75	Dissociation of disease onset, progression and sex differences from androgen receptor levels in a mouse model of amyotrophic lateral sclerosis. <i>Scientific Reports</i> , 2021, 11, 9255.	3.3	3
76	Mapping Motor Neuron Vulnerability in the Neuraxis of Male SOD1G93A Mice Reveals Widespread Loss of Androgen Receptor Occurring Early in Spinal Motor Neurons. <i>Frontiers in Endocrinology</i> , 2022, 13, 808479.	3.5	3
77	Metabolic Dysfunction in Motor Neuron Disease: Shedding Light through the Lens of Autophagy. <i>Metabolites</i> , 2022, 12, 574.	2.9	2
78	The bone morphogenetic protein axis is a positive regulator of skeletal muscle mass. <i>Journal of Experimental Medicine</i> , 2013, 210, 2101201A54.	8.5	1
79	AMPA receptor and RNA processing gene dysregulation are early determinants of selective motor neuron vulnerability in a mouse model of amyotrophic lateral sclerosis. <i>Brain Communications</i> , 2022, 4, fcac081.	3.3	1
80	Advances in Gene Delivery Methods to Label and Modulate Activity of Upper Motor Neurons: Implications for Amyotrophic Lateral Sclerosis. <i>Brain Sciences</i> , 2021, 11, 1112.	2.3	0